Skip to main content
Insights
/ Partnering 2030 / 2024 / Report

Partnering 2030: Biopharma Report

This year's project builds on the success of the Partnering 2030 surveys of 2022 and 2023. In this year's report we again unlock insights from biotechs and out-licensors, dive deep into their partnering experiences at conferences and with top pharmaceutical firms, and reveal the challenges and pain points they face bringing their innovations to market.

Supported by

Share:

Download this free report

Business email
First name
Last name
Company name
Job title
Which sector best reflects your role?
By submitting this form, you agree to the storing and processing of your personal data by Inpart as detailed in the Privacy Statement.

The Biotechs and Research Institutes Perspective

Scientists group
Industry Insights
AI is expected to make positive impacts on the industry while environmental protection efforts are becoming less important
Work people
Partnering conferences
Biotechs prioritize partnering events but struggle to have their meeting requests accepted at expensive conferences
Hands star
Partnering values
Out-licensors value transparency and communication in a partner above all else

Biotech target partner types

Biotech respondents demonstrated a strong preference for partnering with large and midsize pharma companies.

Large pharma companies25%Midsize pharma companies17%Clinical stage biotech companies13%Start-up biotech companies16%Venture Capital or Finance partners26%